MORF Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 25.60%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $7,018,566.18
Morphic Share Price & Price History
Current Price: $56.99
Price Change: +0.30 (1.20%)
As of 08/16/2024 01:00 AM ET
Morphic Insider Trading History
Morphic Institutional Trading History
Data available starting January 2016
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Read More on Morphic
Today's Range
Now: $56.99
52 Week Range
Now: $56.99
Volume
400 shs
Average Volume
1,272,131 shs
Market Capitalization
$2.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.49
Who are the company insiders with the largest holdings of Morphic?
Morphic's top insider shareholders include:
- Timothy A Springer (Director)
- Bruce Rogers (President)
- Praveen P Tipirneni (CEO)
- Marc Schegerin (CFO)
- Robert E Farrell Jr (CAO)
- William Devaul (General Counsel)
- Joseph P Slattery (Director)
Learn More about top insider investors at Morphic.